Skip to main content
Mark Fleming, MD, Oncology, Hampton, VA, Chesapeake Regional Medical Center

MarkTFlemingMD

Oncology Hampton, VA

Physician

Dr. Fleming is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fleming's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Temple University Hospital
    Temple University HospitalResidency, Internal Medicine, 1999 - 2002
  • The University of Toledo College of Medicine
    The University of Toledo College of MedicineClass of 1999

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2006 - 2026
  • NY State Medical License
    NY State Medical License 2003 - 2007
  • NJ State Medical License
    NJ State Medical License 2002 - 2003
  • PA State Medical License
    PA State Medical License 2000 - 2002

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer  
    Mark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research

Press Mentions

  • AUA 2022: Late-Breaking Plenary Highlights
    AUA 2022: Late-Breaking Plenary HighlightsJuly 27th, 2022
  • Creating an Inclusive Environment in Your Oncology Practice with Mark Fleming, MD
    Creating an Inclusive Environment in Your Oncology Practice with Mark Fleming, MDJuly 11th, 2022
  • Oncologists “In a Quandary” over Lack of Second-Line Guidance in Bladder Cancer
    Oncologists “In a Quandary” over Lack of Second-Line Guidance in Bladder CancerFebruary 21st, 2024

Professional Memberships

Hospital Affiliations